The stock of ImmunityBio, Inc. (IBRX) gained in the after-hours when the company announced its promising results for its study. IBRX values at around $6.20, gaining more than 6.5% from the previously closed value. The stock closed at $5.82 at the end of the previously closed session. The stock volume traded in the last trading session was around 1.97 million shares.
IBRX announced clinical study results.
ImmunityBio, Inc. (IBRX) today announced promising study results. ImmunityBio’s (IBRX) IL-15 superagonist shows to activate CD4+ and CD8+ T cells as well as natural killer (NK) cells in HIV patients (N-803). Anktiva activates latent HIV replication in CD4 memory cells, allowing CD8 and NK cells to detect and kill previously concealed infected cells. This method is critical for killing latent virus-carrying cells, lowering viral reservoirs in ART-suppressed HIV patients, and finally eliminating the virus from the body.
Three functions of ImmunityBio’s IL-15 superagonist Anktiva shows to aid the immune system to eradicate HIV reservoirs and manage virus rebound:
- Anktiva demonstrates to reverse HIV latency (where the virus’ genetic code persists, but no virus generates), allowing infected cells to elude identification and destruction by the immune system.
- It activates NK cells and CD8+ T cells, two immune system components that target virus-infected cells.
- It allows NK cells and CD8+ T cells to migrate into lymphoid organs, where they are more likely to encounter and kill HIV-infected cells.
The effect on the stock
IBRX stock gained in the after-hours when they announced its results for the clinical study. Investors are responding positively to the significant development in the study. The stock is volatile after-hours, but it may increase more when the regular trading session starts.
Conclusion
ImmunityBio, Inc. (IBRX) is now in the later stage of drug development. Those companies that reach the trials’ final stages manage to get the FDA approval. IBRX may also get that approval. Investors are betting on the stock seeing the results.
